{"id":934013,"date":"2026-02-04T11:25:09","date_gmt":"2026-02-04T16:25:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/"},"modified":"2026-02-04T11:25:09","modified_gmt":"2026-02-04T16:25:09","slug":"cytomx-therapeutics-to-present-at-upcoming-february-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/","title":{"rendered":"CytomX Therapeutics to Present at Upcoming February Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Feb.  04, 2026  (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February.<\/p>\n<p align=\"justify\">\n        <strong>Guggenheim Emerging Outlook: Biotech Summit 2026<\/strong><br \/>\n        <br \/>Date: Wednesday, February 11, 2026<br \/>Fireside Chat: 4:30 p.m. ET<br \/>Location: New York, NY<\/p>\n<p align=\"justify\">\n        <strong>World ADC London 2026<\/strong><br \/>\n        <br \/>Date: Wednesday, February 25, 2026<br \/>Presentation: 5:00 p.m. GMT<br \/>Location: London, UK<\/p>\n<p>Additional information can be found on the Events and Presentations page of CytomX\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J3Sqf4cuUPFowFuzXzdM9oOMeg45vjVpmEY0TdSHL8cKmqIvI8XXIG23hYHbXDIB3EZ0q-cQmkJkps0hTBt9FA==\" rel=\"nofollow\" target=\"_blank\">www.cytomx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About CytomX Therapeutics, Inc.<br \/><\/strong>CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY<sup>\u00ae<\/sup> therapeutic platform, CytomX\u2019s vision is to create safer, more effective therapies for the treatment of cancer. CytomX\u2019s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (\u201cADCs\u201d), T-cell engagers, and immune modulators such as cytokines. CytomX\u2019s clinical-stage pipeline includes varsetatug masetecan (formerly CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload and was discovered in collaboration with ImmunoGen, now part of AbbVie. EpCAM is a highly expressed but previously undruggable tumor antigen due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and deliver meaningful anti-cancer activity in solid tumors, including CRC. CX-801 is a masked interferon alpha-2b PROBODY<sup>\u00ae <\/sup>cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J3Sqf4cuUPFowFuzXzdM9outov5eE1NyIP5Un6wrj_iNPL3I7qa1QMxQvqL_6N3FeP03TOwY5smX_QnNvI-ZeHv9DJF2iBqdDzIP2JgH_BpN_g8w2wN_jFcqJQYdZHIFYT7NXUd9lcEqDqXwBmEp6WdVPgD2hIPiXIMYyD3Kg2u_v98FHjWA8yrtNdtpekGbItFxL3aLaDyRzRCEnUj2lfrcs4KdsQl6jgwwy9fg94U=\" rel=\"nofollow\" target=\"_blank\"><strong>www.cytomx.com<\/strong><\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NopK0u-d12fRNwoduJygm3W_p5k23x4Wz6jgiiJIoETUnmHXWT0iOZ_eZSJVCluuQpz6Vngqe-H3LD609R8XlqdHWXXHDmw1hTigqWgG2ucG7X7qGB38aOHwg9eq_NE8kmFJc7vAeAmTlAcJOpNq2_ituFphz7fjodsPkKTCbqMFBFcr8JD5iNeeA-7Port8K7R04As0WtAFwDojvwcdZb3iqm7YH6j_BnxILMENUvCu70ALKPL2dgLSSUDgrH3bSQyu0pWLQgydSp70Qaqm2A==\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V-PaCn7HWqauUCGsHfRdq-oNsrjC6sfWGftoSxYRNQg3paGuz9rYAfdfB26XJ9qSG6TAuS3XPEr-Y1L2haUexWhnh8jrhUIF4p8CMdmKgiDZbiK89P6RFmz7jzE7IGFVgJg9octgWpotADQL9eWp3lAgjL1h-HhUMoAyn53qHKt-QztGn_0NBNg5dqmEfMXbw1A15bMsQkA7-11h1HdrDK7bGsHiaJvc6ZByo2vm1ptoEPvM-v9jKP4foGD6H-jP\" rel=\"nofollow\" target=\"_blank\"><strong>X<\/strong><\/a><strong><u> (formerly Twitter)<\/u><\/strong>.<\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Chris Ogden<br \/>SVP, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r5oBsEtm7xBP8SWls3MaE8JX40Ipeb143BWEEIHJzqfTmDYogDjiizta4x8SBPzoq8hz2RvSkKZ77MYTjMVnhVxKFEkgtIwpyj0jNmZhQ-Y=\" rel=\"nofollow\" target=\"_blank\">cogden@cytomx.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Precision AQ (formerly Stern Investor Relations)<br \/>Stephanie Ascher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uHUCEQHO8QDhlQ1_Q2-b1GynN-HzSQLgceNpAzN7O5wNHZtjfHtm6hW2KAi5wq6mMIU8inwl2DY9OsxcN3kS8sQ3zGw_Sgs75N9_hNyIWgrcUQ9PNquwi1u-Wci4OLbANjDvxkUkRKbi2_bl8IC3pQ==\" rel=\"nofollow\" target=\"_blank\">stephanie.ascher@precisionaq.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Precision AQ<br \/>Colleen Ketchum<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SrcaQjlV7iO3GC-SxhsyiI4pTUJ0i4bwqUJHVHVH1kHcC06BRv59Mb-B9s8dZS6hoJNjpDGIn7M168IoYBmcx8LfNrNQHC4FR_RfeSD9cvDsMkdn1rgYdnphtomtYejr\" rel=\"nofollow\" target=\"_blank\">colleen.ketchum@precisionaq.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmU2YzlkNjItYTIxYi00ODI2LThjNzMtNjY4ODhjOGE0NmYxLTEwMzE3OTktMjAyNi0wMi0wNC1lbg==\/tiny\/CytomX-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February. Guggenheim Emerging Outlook: Biotech Summit 2026 Date: Wednesday, February 11, 2026Fireside Chat: 4:30 p.m. ETLocation: New York, NY World ADC London 2026 Date: Wednesday, February 25, 2026Presentation: 5:00 p.m. GMTLocation: London, UK Additional information can be found on the Events and Presentations page of CytomX\u2019s website at www.cytomx.com. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytomX Therapeutics to Present at Upcoming February Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-934013","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytomX Therapeutics to Present at Upcoming February Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytomX Therapeutics to Present at Upcoming February Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February. Guggenheim Emerging Outlook: Biotech Summit 2026 Date: Wednesday, February 11, 2026Fireside Chat: 4:30 p.m. ETLocation: New York, NY World ADC London 2026 Date: Wednesday, February 25, 2026Presentation: 5:00 p.m. GMTLocation: London, UK Additional information can be found on the Events and Presentations page of CytomX\u2019s website at www.cytomx.com. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered &hellip; Continue reading &quot;CytomX Therapeutics to Present at Upcoming February Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T16:25:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytomX Therapeutics to Present at Upcoming February Conferences\",\"datePublished\":\"2026-02-04T16:25:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/\"},\"wordCount\":363,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/\",\"name\":\"CytomX Therapeutics to Present at Upcoming February Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=\",\"datePublished\":\"2026-02-04T16:25:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytomX Therapeutics to Present at Upcoming February Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytomX Therapeutics to Present at Upcoming February Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/","og_locale":"en_US","og_type":"article","og_title":"CytomX Therapeutics to Present at Upcoming February Conferences - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February. Guggenheim Emerging Outlook: Biotech Summit 2026 Date: Wednesday, February 11, 2026Fireside Chat: 4:30 p.m. ETLocation: New York, NY World ADC London 2026 Date: Wednesday, February 25, 2026Presentation: 5:00 p.m. GMTLocation: London, UK Additional information can be found on the Events and Presentations page of CytomX\u2019s website at www.cytomx.com. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered &hellip; Continue reading \"CytomX Therapeutics to Present at Upcoming February Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-04T16:25:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytomX Therapeutics to Present at Upcoming February Conferences","datePublished":"2026-02-04T16:25:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/"},"wordCount":363,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/","name":"CytomX Therapeutics to Present at Upcoming February Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=","datePublished":"2026-02-04T16:25:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODAxMiM3NDA2NzE5IzIwMjAyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-february-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytomX Therapeutics to Present at Upcoming February Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=934013"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934013\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=934013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=934013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=934013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}